ConductScience.org, home

Paper26324372

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

Kelly K and 15 others. J Clin Oncol, 2015. Cited by 381 papers, by iCite.

Cite this record

ConductScience Library. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. Papers, record 26324372. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26324372

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
PubMed
Journal
J Clin Oncol
PubMed
Year
2015
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
381
iCite
Relative citation ratio, by iCite
10.6
iCite
Revised in PubMed
2022-04-08
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kelly KKaren
2Altorki NKNasser K
3Eberhardt WEWilfried E E
4O'Brien MEMary E R
5Spigel DRDavid R
6Crinò LLucio
7Tsai CMChun-Ming
8Kim JHJoo-Hang
9Cho EKEun Kyung
10Hoffman PCPhilip C
11Orlov SVSergey V
12Serwatowski PPiotr
13Wang JJiuzhou
14Foley MAMargaret A
15Horan JDJulie D
16Shepherd FAFrances A

Source PubMed

Download CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Carcinoma, Non-Small-Cell LungMajor topic
Erlotinib HydrochlorideMajor topic
Lung NeoplasmsMajor topic
Adult
Aged
Aged, 80 and over
Chemotherapy, Adjuvant
Double-Blind Method
ErbB Receptors
Female
Follow-Up Studies
Humans
International Agencies
Male
Middle Aged
Mutation
Neoplasm Staging
Prognosis
Survival Rate
Young Adult

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00373425A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive TumorsDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in26438112Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non-Small-Cell Lung Cancer.https://conductscience.org/library/papers/26438112PubMed
Comment in26552954Adjuvant TKIs in NSCLC: what can we learn from RADIANT?https://conductscience.org/library/papers/26552954PubMed
Comment in27568486Have adjuvant tyrosine kinase inhibitors lost their shine?https://conductscience.org/library/papers/27568486PubMed

Download CSV of comments and corrections

Cited by220

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 381 citations.

PMIDTitleJournalYearIn PapersSource
42894004Oncogenic mutations in non-small cell lung cancer: from molecular mechanisms to clinical practice.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42894004PubMed
42867814A Podcast on Osimertinib After CRT in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): Current and Future Perspectives.Target Oncol2026https://conductscience.org/library/papers/42867814PubMed
42700335The Efficacy of Adjuvant EGFR-TKI Therapy for Stage IA Lung Adenocarcinoma with EGFR Mutations: A Retrospective Cohort Study.Ann Surg Oncol2026https://conductscience.org/library/papers/42700335PubMed
42660909Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42660909PubMed
42625890Efficacy and safety of almonertinib as adjuvant therapy in stage II-IIIA EGFR-mutant non-small cell lung cancer: a retrospective study.Front Med (Lausanne)2026https://conductscience.org/library/papers/42625890PubMed
42588620Targeting Classical EGFR Mutations in Lung Cancer: Twenty Years of Progress and Beyond.Cancers (Basel)2026https://conductscience.org/library/papers/42588620PubMed
42564402Target-specific cardiotoxicity of tyrosine kinase inhibitors: a Systematic Review and meta-analysis.Front Pharmacol2026https://conductscience.org/library/papers/42564402PubMed
42299229Adjuvant epidermal growth factor receptor tyrosine kinase inhibitor in resected stage N2 non-small cell lung cancer harboring EGFR mutation.Transl Lung Cancer Res2026https://conductscience.org/library/papers/42299229PubMed
42038290
Clinical efficacy of comprehensive traditional Chinese medicine in adjuvant therapy for stage Ib-IIIa resected non-small cell lung cancer: a multi-center, randomized, double-blind, placebo-controlled trial.
Front Pharmacol2026https://conductscience.org/library/papers/42038290PubMed
41964727Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC).Curr Oncol Rep2026https://conductscience.org/library/papers/41964727PubMed
41953249Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With EGFR Mutation (West Japan Oncology Group 11719L: ADJUST Study).JTO Clin Res Rep2026https://conductscience.org/library/papers/41953249PubMed
41736521Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).Chin Med J (Engl)2026https://conductscience.org/library/papers/41736521PubMed
41701181CyberKnife radical cure for early lung adenocarcinoma: a case was confirmed by postoperative pathology.Lung Cancer Manag2026https://conductscience.org/library/papers/41701181PubMed
41681965Neoadjuvant, Adjuvant and Perioperative Treatment in Early-Stage Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations: Current Landscape and Future Perspectives.Cancers (Basel)2026https://conductscience.org/library/papers/41681965PubMed
41590340A Canadian Perspective on Perioperative Systemic Therapy in Resectable Non-Small Cell Lung Cancer.Curr Oncol2025https://conductscience.org/library/papers/41590340PubMed
40866342Adjuvant icotinib for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study.Signal Transduct Target Ther2025https://conductscience.org/library/papers/40866342PubMed
40596078A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancer.Sci Rep2025https://conductscience.org/library/papers/40596078PubMed
40565872Systemic Therapy for Operable NSCLC: A Review of the Literature and Discussion of Future Directions.J Clin Med2025https://conductscience.org/library/papers/40565872PubMed
40524802Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trial.EClinicalMedicine2025https://conductscience.org/library/papers/40524802PubMed
40507325Perioperative Strategies in Resectable Non-Squamous Non-Small Cell Lung Cancer with EGFR Mutations and ALK Rearrangement.Cancers (Basel)2025https://conductscience.org/library/papers/40507325PubMed

See all 220 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
ERLOTINIBCHEMBL553Derived from the trial1https://conductscience.org/library/drugs/CHEMBL553

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26324372

GET https://conductscience.org/api/papers/v1/26324372/cited_by?page=2